SQZ vs. CISS, OP, GVH, USDP, AIRTP, BLDEW, RA, EDRY, HSHP, and IMPPP
Should you be buying SQZ Biotechnologies stock or one of its competitors? The main competitors of SQZ Biotechnologies include C3is (CISS), OceanPal (OP), Globavend (GVH), USD Partners (USDP), Air T (AIRTP), Blade Air Mobility (BLDEW), Brookfield Real Assets Income Fund (RA), EuroDry (EDRY), Himalaya Shipping (HSHP), and Imperial Petroleum (IMPPP). These companies are all part of the "transportation" industry.
SQZ Biotechnologies vs. Its Competitors
C3is (NASDAQ:CISS) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap transportation companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.
C3is has a net margin of 20.51% compared to SQZ Biotechnologies' net margin of -369.96%. C3is' return on equity of 5.41% beat SQZ Biotechnologies' return on equity.
In the previous week, C3is had 1 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 1 mentions for C3is and 0 mentions for SQZ Biotechnologies. C3is' average media sentiment score of 1.91 beat SQZ Biotechnologies' score of 0.00 indicating that C3is is being referred to more favorably in the media.
C3is has higher revenue and earnings than SQZ Biotechnologies. C3is is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.
C3is has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500. Comparatively, SQZ Biotechnologies has a beta of 2.34, indicating that its share price is 134% more volatile than the S&P 500.
10.5% of C3is shares are owned by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are owned by institutional investors. 16.0% of SQZ Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
C3is beats SQZ Biotechnologies on 8 of the 13 factors compared between the two stocks.
Get SQZ Biotechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for SQZ and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SQZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SQZ Biotechnologies Competitors List
Related Companies and Tools
This page (NYSE:SQZ) was last updated on 9/14/2025 by MarketBeat.com Staff
Free SQZ Stock Alerts